NCT07189169

QA108 Phase III Study in Subjects With Intermediate AMD

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Clinical Study of the Efficacy and Safety of QA108 Granules in the Treatment of Intermediate Age-Related Macular Degeneration (Type of Yang-Hyperactivity Due to Yin-Deficiency)

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: Smilebiotek Zhuhai Limited · Industry
• Sex: All
• Age: 45 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This is a phase III randomized, double-masked, placebo-controlled, multicenter study. To evaluate the efficacy and safety of QA108 granules in the treatment of intermediate age-related macular degeneration.

Conditions

• Intermediate Age-Related Macular Degeneration

Interventions

Type	Name	Description
DRUG	QA108 granules	Take the medication as required for 24 weeks
DRUG	QA108 granules placebo	Take the medication as required for 24 weeks

Timeline

• Start date: 2025-07-08
• Primary completion: 2027-03-01
• Completion: 2027-06-30
• First posted: 2025-09-23
• Last updated: 2025-09-23

Locations

1 site across 1 country: China